Features associated with an increased likelihood of developing ICANS include a high baseline tumor burden [90], greater CAR T cell expansion [85], an earlier and more severe systemic inflammatory response called cytokine release syndrome (CRS) (with high peak ferritin and C-reactive protein levels) [91,92,93], and chimeric receptors with a CD28 co-stimulatory signaling domain [85,94,95]. The gene discussed is CRP; the disease is congenital rubella syndrome.